Showing 2381-2390 of 5644 results for "".
- Treehouse Eyes Partners with J&J Vision to Deliver Treatment Innovation for Myopia Management: Acuvue Abiliti Overnight Therapeutic Lenseshttps://modernod.com/news/treehouse-eyes-partners-with-jj-vision-to-deliver-treatment-innovation-for-myopia-management-acuvue-abiliti-overnight-therapeutic-lenses/2480497/Treehouse Eyes, a health care business dedicated exclusively to treating myopic chi
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Amydis Has Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALShttps://modernod.com/news/amydis-has-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/2480493/Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients. The FDA agreed with the overall d
- CoFi Announces 300 Eye Care Practices Now Use CoFi’s Compliant Co-Management Payments Tool for Ophthalmology Procedureshttps://modernod.com/news/cofi-announces-300-eye-care-practices-now-use-cofis-compliant-co-management-payments-tool-for-ophthalmology-procedures/2480490/CoFi, a provider of a multi-party payments platform for elective medical procedures, announced the growing adoption of its co-management payment solution for ophthalmology procedures with more than 300 practices now using CoFi. Throughout ophthalmology, there i
- Omeros to Sell Omidria Franchise to Rayner in a Deal Worth More Than $1 Billionhttps://modernod.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/Omeros announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group. The transaction, which is expected to close on or before December 31, 2021, includes an upfront payment of $125 million with an additional $200 million in
- Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Devicehttps://modernod.com/news/kubota-vision-announces-publication-in-scientific-reports-of-study-data-for-wearable-myopia-control-device/2480478/Kubota Vision announced the publication of a new paper in the journal Scientific Reports: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans. The paper
- Heidelberg Engineering Receives European Acceptance for Spectralis Shift Technology Under New Medical Device Regulationhttps://modernod.com/news/heidelberg-engineering-receives-european-acceptance-for-spectralis-shift-technology-under-new-medical-device-regulation/2480442/Heidelberg Engineering announced the launch of the Spectralis platform with shift technology, which is designed to create synergies that significantly increase efficiency in both OCT and OCTA, and deliver images with more detail. Shift enables clinicians to switch between OCT scan
- CXL Ophthalmics to Present Phase 2 Clinical Trial Results in Epi-On Cross-linking on November 14 at American Academy of Ophthalmologyhttps://modernod.com/news/cxl-ophthalmics-to-present-phase-2-clinical-trial-results-in-epi-on-cross-linking-on-november-14-at-american-academy-of-ophthalmology/2480421/CXL Ophthalmics announced that the results of CXL-005, a phase 2 Trial in transepithelial (Epi-On) cross-linking, will be featured in the “Hot Topics 2021” session at AAO on November
- Novartis to Sell Roche Stake for $20.7 Billionhttps://modernod.com/news/novartis-to-sell-roche-stake-for-207-billion/2480406/Novartis said Thursday that it agreed to sell its stake in Roche for $20.7 billion, with the proceeds to be used "in line with capital allocation priorities to enhance strong returns to shareholders," according to a FirstWord repor
- Tarsus Pharmaceuticals Presents Data from Two Studies on the Prevalence and Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/Tarsus Pharmaceuticals presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for ov